Status:
RECRUITING
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Lead Sponsor:
Centre Hospitalier Universitaire de Liege
Collaborating Sponsors:
SYSNAV
Centre Hospitalier Régional de la Citadelle
Conditions:
Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility:
All Genders
18-99 years
Brief Summary
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of appr...
Detailed Description
On each visit, participants will undergo a clinical examination with MRC sum score, a mISS score and a I-RODS score. They will perform few tests 6-minutes walk test (6MWT), a myogrip measurement, and...
Eligibility Criteria
Inclusion
- Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
- Treated with IVIg (≤1g/kg/3-8week)
- Clinically Stable disease for 3 months (according to treating physician opinion).
- No treatment withdrawal failure within 1 year
- Age over 18 years
Exclusion
- Significant cognitive or communication disorders
- Surgery or serious traumatic injury ≤ 6 months
- Non ambulant patient
- Current participation to a therapeutic trial
- Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
- Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment
- Pregnancy or breastfeeding
- Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.
Key Trial Info
Start Date :
August 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06183645
Start Date
August 28 2023
End Date
January 1 2028
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHR Citadelle
Liège, Liège, Belgium, 4000